Pathstone Family Office, LLC Crispr Therapeutics Ag Transaction History

Pathstone Family Office, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 23, 2023	BUY	$61.1 - $83.78 $2,016 - $2,764	33 Added 0.84%	3,948 $258,000
Q3 2022 Nov 14, 2022	BUY	$61.1 - $83.78 $2,016 - $2,764	33 Added 0.84%	3,948 $258,000
Q2 2022 Oct 23, 2023	BUY	$43.23 - $73.83 $169,245 - $289,044	3,915 New	3,915 $237,000
Q2 2022 Aug 15, 2022	SELL	$43.23 - $73.83 $931,606 - $1.59 Million	-21,550 Reduced 84.63%	3,915 $238,000
Q1 2022 May 16, 2022	BUY	$53.19 - $79.24 $1.14 Million - $1.7 Million	21,464 Added 536.47%	25,465 $1.6 Million
Q4 2021 Feb 14, 2022	BUY	$70.09 - $111.29 $138,497 - $219,909	1,976 Added 97.58%	4,001 $303,000
Q3 2021 Nov 16, 2021	BUY	$110.2 - $156.64 $40,112 - $57,016	364 Added 21.91%	2,025 $226,000
Q2 2021 Aug 31, 2021	BUY	$100.84 - $161.89 $167,495 - $268,899	1,661 New	1,661 $269,000

503

57M

1.7M

1.8M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.03B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

Stay updated on Pathstone Family Office, LLC with notifications on news.